Healthcare provider profile · identity verified

Denis Mee-Lee, MD

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · HONOLULU, HI · NPI 1730132416

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Denis Mee-Lee, MD received $99,484.04 in general payments during 2025 across 298 reported records.

Teva Pharmaceuticals USA, Inc. accounted for 27.1% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 18 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Abilify Maintena, Aristada, Austedo Xr, Ingrezza, Invega Sustenna, Lybalvi, Rexulti, Trintellix, Uzedy, Vraylar.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Vraylar by this doctor in 2024.

Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARISTADA as an associated drug or biological on 76041 records involving 17486 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Aristada by this doctor in 2024.

Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Lybalvi by this doctor in 2024.

Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Invega Sustenna by this doctor in 2024.

Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Abilify Maintena by this doctor in 2024.

Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Rexulti by this doctor in 2024.

Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ingrezza by this doctor in 2024.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Abilify Maintena by this doctor in 2024.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Rexulti by this doctor in 2024.

Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 87 records involving 83 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Abilify Maintena by this doctor in 2024.

Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Rexulti by this doctor in 2024.

Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Trintellix by this doctor in 2024.

Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Austedo Xr by this doctor in 2024.

Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UZEDY as an associated drug or biological on 46702 records involving 13355 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Uzedy by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$99,484.04

298 reported records · 14 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Teva Pharmaceuticals USA, Inc.	Unresolved — no canonical attribution shown	$26,989.17	27.1%	53	2025
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	Unresolved — no canonical attribution shown	$21,250.18	21.4%	60	2025
Otsuka America Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$17,625.94	17.7%	30	2025
Neurocrine BioSciences, Inc.	Unresolved — no canonical attribution shown	$17,084.87	17.2%	28	2025
ABBVIE INC.	Unresolved — no canonical attribution shown	$14,727.33	14.8%	35	2025
Alkermes, Inc.	Unresolved — no canonical attribution shown	$496.96	0.5%	27	2025
Vanda Pharmaceuticals Inc.	Unresolved — no canonical attribution shown	$340.12	0.3%	17	2025
E.R. Squibb & Sons, L.L.C.	Unresolved — no canonical attribution shown	$297.89	0.3%	13	2025
Lundbeck LLC	Unresolved — no canonical attribution shown	$294.44	0.3%	16	2025
Janssen Pharmaceuticals, Inc	Unresolved — no canonical attribution shown	$215.07	0.2%	12	2025
Otsuka Pharmaceutical Development & Commercialization, Inc.	Unresolved — no canonical attribution shown	$72.02	0.1%	3	2025
Axsome Therapeutics, Inc.	Unresolved — no canonical attribution shown	$50.92	0.1%	2	2025
Luye Pharma (USA) Ltd.	Unresolved — no canonical attribution shown	$22.84	0.0%	1	2025
Takeda Pharmaceuticals U.S.A., Inc.	Unresolved — no canonical attribution shown	$16.29	0.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	$74,020.50	26
Consulting Fee	$12,500.00	3
Food and Beverage	$6,894.82	254
Travel and Lodging	$5,944.23	14
Education	$124.49	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
CAPLYTA Normalized: caplyta	Drug	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	$21,250.18	60	2025
Source payment records 2025-01-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $34.86 · Open Payments source 2025-01-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3.12 · Open Payments source 2025-01-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $9.65 · Open Payments source 2025-01-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $26.85 · Open Payments source 2025-02-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $32.93 · Open Payments source 2025-02-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.68 · Open Payments source 2025-02-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $33.20 · Open Payments source 2025-02-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,160.00 · Open Payments source 2025-02-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $34.88 · Open Payments source 2025-03-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $31.16 · Open Payments source 2025-03-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,860.00 · Open Payments source 2025-03-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $104.80 · Open Payments source 2025-03-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $23.25 · Open Payments source 2025-03-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4.59 · Open Payments source 2025-04-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.51 · Open Payments source 2025-04-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $29.43 · Open Payments source 2025-04-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.46 · Open Payments source 2025-05-01 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1.96 · Open Payments source 2025-05-01 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3.74 · Open Payments source 2025-05-01 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $7.85 · Open Payments source 2025-05-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $5.45 · Open Payments source 2025-06-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.69 · Open Payments source 2025-06-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.59 · Open Payments source 2025-07-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.94 · Open Payments source 2025-07-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $30.23 · Open Payments source 2025-07-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $13.48 · Open Payments source 2025-08-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $11.82 · Open Payments source 2025-08-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1.08 · Open Payments source 2025-08-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $26.59 · Open Payments source 2025-08-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,220.00 · Open Payments source 2025-08-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $23.11 · Open Payments source 2025-09-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.62 · Open Payments source 2025-09-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.00 · Open Payments source 2025-09-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.93 · Open Payments source 2025-10-01 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.88 · Open Payments source 2025-10-01 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1.17 · Open Payments source 2025-10-01 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $0.23 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $138.53 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $230.00 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $230.00 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.29 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.29 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $46.64 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $52.94 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $550.90 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $59.43 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $905.80 · Open Payments source 2025-10-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $29.52 · Open Payments source 2025-10-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $13.87 · Open Payments source 2025-10-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $6.81 · Open Payments source 2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,220.00 · Open Payments source 2025-11-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.97 · Open Payments source 2025-11-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $34.70 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.08 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-12-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $30.88 · Open Payments source 2025-12-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $13.59 · Open Payments source 2025-12-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.21 · Open Payments source 2025-12-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $35.00 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,220.00 · Open Payments source
ABILIFY ASIMTUFII Normalized: abilify asimtufii	Drug	Otsuka America Pharmaceutical, Inc.	$17,547.54	25	2025
Source payment records 2025-01-15 · Otsuka America Pharmaceutical, Inc. · $6.48 · Open Payments source 2025-01-28 · Otsuka America Pharmaceutical, Inc. · $28.29 · Open Payments source 2025-02-11 · Otsuka America Pharmaceutical, Inc. · $23.96 · Open Payments source 2025-02-21 · Otsuka America Pharmaceutical, Inc. · $150.00 · Open Payments source 2025-02-21 · Otsuka America Pharmaceutical, Inc. · $184.80 · Open Payments source 2025-03-05 · Otsuka America Pharmaceutical, Inc. · $4,752.00 · Open Payments source 2025-04-09 · Otsuka America Pharmaceutical, Inc. · $7.10 · Open Payments source 2025-04-09 · Otsuka America Pharmaceutical, Inc. · $7.14 · Open Payments source 2025-04-16 · Otsuka America Pharmaceutical, Inc. · $351.00 · Open Payments source 2025-05-19 · Otsuka America Pharmaceutical, Inc. · $31.01 · Open Payments source 2025-05-22 · Otsuka America Pharmaceutical, Inc. · $23.48 · Open Payments source 2025-06-12 · Otsuka America Pharmaceutical, Inc. · $6.40 · Open Payments source 2025-06-24 · Otsuka America Pharmaceutical, Inc. · $125.00 · Open Payments source 2025-06-25 · Otsuka America Pharmaceutical, Inc. · $877.50 · Open Payments source 2025-08-14 · Otsuka America Pharmaceutical, Inc. · $8.91 · Open Payments source 2025-09-03 · Otsuka America Pharmaceutical, Inc. · $25.75 · Open Payments source 2025-09-11 · Otsuka America Pharmaceutical, Inc. · $144.67 · Open Payments source 2025-09-11 · Otsuka America Pharmaceutical, Inc. · $164.61 · Open Payments source 2025-09-18 · Otsuka America Pharmaceutical, Inc. · $4,752.00 · Open Payments source 2025-10-09 · Otsuka America Pharmaceutical, Inc. · $122.81 · Open Payments source 2025-10-16 · Otsuka America Pharmaceutical, Inc. · $97.04 · Open Payments source 2025-10-24 · Otsuka America Pharmaceutical, Inc. · $2,808.00 · Open Payments source 2025-11-14 · Otsuka America Pharmaceutical, Inc. · $2,808.00 · Open Payments source 2025-11-25 · Otsuka America Pharmaceutical, Inc. · $21.31 · Open Payments source 2025-12-23 · Otsuka America Pharmaceutical, Inc. · $20.28 · Open Payments source
ABILIFY MAINTENA Normalized: abilify maintena	Drug	Otsuka America Pharmaceutical, Inc.	$17,516.53	24	2025
Source payment records 2025-01-15 · Otsuka America Pharmaceutical, Inc. · $6.48 · Open Payments source 2025-01-28 · Otsuka America Pharmaceutical, Inc. · $28.29 · Open Payments source 2025-02-11 · Otsuka America Pharmaceutical, Inc. · $23.96 · Open Payments source 2025-02-21 · Otsuka America Pharmaceutical, Inc. · $150.00 · Open Payments source 2025-02-21 · Otsuka America Pharmaceutical, Inc. · $184.80 · Open Payments source 2025-03-05 · Otsuka America Pharmaceutical, Inc. · $4,752.00 · Open Payments source 2025-04-09 · Otsuka America Pharmaceutical, Inc. · $7.10 · Open Payments source 2025-04-09 · Otsuka America Pharmaceutical, Inc. · $7.14 · Open Payments source 2025-04-16 · Otsuka America Pharmaceutical, Inc. · $351.00 · Open Payments source 2025-05-22 · Otsuka America Pharmaceutical, Inc. · $23.48 · Open Payments source 2025-06-12 · Otsuka America Pharmaceutical, Inc. · $6.40 · Open Payments source 2025-06-24 · Otsuka America Pharmaceutical, Inc. · $125.00 · Open Payments source 2025-06-25 · Otsuka America Pharmaceutical, Inc. · $877.50 · Open Payments source 2025-08-14 · Otsuka America Pharmaceutical, Inc. · $8.91 · Open Payments source 2025-09-03 · Otsuka America Pharmaceutical, Inc. · $25.75 · Open Payments source 2025-09-11 · Otsuka America Pharmaceutical, Inc. · $144.67 · Open Payments source 2025-09-11 · Otsuka America Pharmaceutical, Inc. · $164.61 · Open Payments source 2025-09-18 · Otsuka America Pharmaceutical, Inc. · $4,752.00 · Open Payments source 2025-10-09 · Otsuka America Pharmaceutical, Inc. · $122.81 · Open Payments source 2025-10-16 · Otsuka America Pharmaceutical, Inc. · $97.04 · Open Payments source 2025-10-24 · Otsuka America Pharmaceutical, Inc. · $2,808.00 · Open Payments source 2025-11-14 · Otsuka America Pharmaceutical, Inc. · $2,808.00 · Open Payments source 2025-11-25 · Otsuka America Pharmaceutical, Inc. · $21.31 · Open Payments source 2025-12-23 · Otsuka America Pharmaceutical, Inc. · $20.28 · Open Payments source
INGREZZA Normalized: ingrezza	Drug	Neurocrine BioSciences, Inc.	$17,084.87	28	2025
Source payment records 2025-03-07 · Neurocrine BioSciences, Inc. · $179.12 · Open Payments source 2025-03-07 · Neurocrine BioSciences, Inc. · $175.00 · Open Payments source 2025-03-08 · Neurocrine BioSciences, Inc. · $485.94 · Open Payments source 2025-03-08 · Neurocrine BioSciences, Inc. · $61.72 · Open Payments source 2025-03-08 · Neurocrine BioSciences, Inc. · $54.80 · Open Payments source 2025-03-08 · Neurocrine BioSciences, Inc. · $45.50 · Open Payments source 2025-03-08 · Neurocrine BioSciences, Inc. · $37.65 · Open Payments source 2025-03-08 · Neurocrine BioSciences, Inc. · $32.29 · Open Payments source 2025-03-08 · Neurocrine BioSciences, Inc. · $9.85 · Open Payments source 2025-03-08 · Neurocrine BioSciences, Inc. · $6.60 · Open Payments source 2025-03-09 · Neurocrine BioSciences, Inc. · $1,653.47 · Open Payments source 2025-03-10 · Neurocrine BioSciences, Inc. · $34.81 · Open Payments source 2025-04-03 · Neurocrine BioSciences, Inc. · $7,600.00 · Open Payments source 2025-05-08 · Neurocrine BioSciences, Inc. · $18.15 · Open Payments source 2025-06-04 · Neurocrine BioSciences, Inc. · $38.14 · Open Payments source 2025-07-01 · Neurocrine BioSciences, Inc. · $27.94 · Open Payments source 2025-07-16 · Neurocrine BioSciences, Inc. · $32.43 · Open Payments source 2025-07-17 · Neurocrine BioSciences, Inc. · $4.42 · Open Payments source 2025-08-21 · Neurocrine BioSciences, Inc. · $31.22 · Open Payments source 2025-09-10 · Neurocrine BioSciences, Inc. · $6.17 · Open Payments source 2025-09-10 · Neurocrine BioSciences, Inc. · $5.24 · Open Payments source 2025-09-22 · Neurocrine BioSciences, Inc. · $3,088.00 · Open Payments source 2025-09-22 · Neurocrine BioSciences, Inc. · $28.06 · Open Payments source 2025-09-30 · Neurocrine BioSciences, Inc. · $3,088.00 · Open Payments source 2025-09-30 · Neurocrine BioSciences, Inc. · $156.86 · Open Payments source 2025-10-06 · Neurocrine BioSciences, Inc. · $150.70 · Open Payments source 2025-12-10 · Neurocrine BioSciences, Inc. · $22.35 · Open Payments source 2025-12-11 · Neurocrine BioSciences, Inc. · $10.44 · Open Payments source
VRAYLAR Normalized: vraylar	Drug	ABBVIE INC.	$14,727.33	35	2025
Source payment records 2025-01-22 · ABBVIE INC. · $26.80 · Open Payments source 2025-02-18 · ABBVIE INC. · $13.65 · Open Payments source 2025-03-11 · ABBVIE INC. · $2,750.00 · Open Payments source 2025-04-02 · ABBVIE INC. · $29.04 · Open Payments source 2025-04-10 · ABBVIE INC. · $30.34 · Open Payments source 2025-05-15 · ABBVIE INC. · $15.97 · Open Payments source 2025-05-20 · ABBVIE INC. · $31.63 · Open Payments source 2025-06-18 · ABBVIE INC. · $10.37 · Open Payments source 2025-06-24 · ABBVIE INC. · $24.83 · Open Payments source 2025-06-26 · ABBVIE INC. · $125.00 · Open Payments source 2025-07-03 · ABBVIE INC. · $33.61 · Open Payments source 2025-07-08 · ABBVIE INC. · $18.65 · Open Payments source 2025-07-17 · ABBVIE INC. · $2,750.00 · Open Payments source 2025-07-23 · ABBVIE INC. · $1.40 · Open Payments source 2025-07-23 · ABBVIE INC. · $23.13 · Open Payments source 2025-08-06 · ABBVIE INC. · $31.81 · Open Payments source 2025-08-13 · ABBVIE INC. · $26.51 · Open Payments source 2025-08-26 · ABBVIE INC. · $28.39 · Open Payments source 2025-08-28 · ABBVIE INC. · $124.99 · Open Payments source 2025-09-11 · ABBVIE INC. · $2,750.00 · Open Payments source 2025-09-23 · ABBVIE INC. · $28.94 · Open Payments source 2025-09-23 · ABBVIE INC. · $2,750.00 · Open Payments source 2025-09-23 · ABBVIE INC. · $124.99 · Open Payments source 2025-09-27 · ABBVIE INC. · $19.26 · Open Payments source 2025-09-30 · ABBVIE INC. · $13.50 · Open Payments source 2025-10-09 · ABBVIE INC. · $27.75 · Open Payments source 2025-10-23 · ABBVIE INC. · $14.67 · Open Payments source 2025-10-30 · ABBVIE INC. · $6.76 · Open Payments source 2025-11-05 · ABBVIE INC. · $20.45 · Open Payments source 2025-11-14 · ABBVIE INC. · $33.67 · Open Payments source 2025-11-20 · ABBVIE INC. · $25.65 · Open Payments source 2025-12-03 · ABBVIE INC. · $18.86 · Open Payments source 2025-12-04 · ABBVIE INC. · $2,750.00 · Open Payments source 2025-12-04 · ABBVIE INC. · $21.28 · Open Payments source 2025-12-17 · ABBVIE INC. · $25.43 · Open Payments source
UZEDY Normalized: uzedy	Drug	Teva Pharmaceuticals USA, Inc.	$14,461.45	15	2025
Source payment records 2025-02-11 · Teva Pharmaceuticals USA, Inc. · $2,380.00 · Open Payments source 2025-02-11 · Teva Pharmaceuticals USA, Inc. · $122.79 · Open Payments source 2025-04-01 · Teva Pharmaceuticals USA, Inc. · $8.39 · Open Payments source 2025-05-16 · Teva Pharmaceuticals USA, Inc. · $284.40 · Open Payments source 2025-05-16 · Teva Pharmaceuticals USA, Inc. · $3,570.00 · Open Payments source 2025-05-16 · Teva Pharmaceuticals USA, Inc. · $108.29 · Open Payments source 2025-10-28 · Teva Pharmaceuticals USA, Inc. · $22.62 · Open Payments source 2025-11-13 · Teva Pharmaceuticals USA, Inc. · $26.59 · Open Payments source 2025-11-20 · Teva Pharmaceuticals USA, Inc. · $2,380.00 · Open Payments source 2025-11-20 · Teva Pharmaceuticals USA, Inc. · $125.00 · Open Payments source 2025-11-30 · Teva Pharmaceuticals USA, Inc. · $420.00 · Open Payments source 2025-12-11 · Teva Pharmaceuticals USA, Inc. · $11.00 · Open Payments source 2025-12-18 · Teva Pharmaceuticals USA, Inc. · $863.17 · Open Payments source 2025-12-18 · Teva Pharmaceuticals USA, Inc. · $4,046.00 · Open Payments source 2025-12-18 · Teva Pharmaceuticals USA, Inc. · $93.20 · Open Payments source
AUSTEDO XR Normalized: austedo xr	Drug	Teva Pharmaceuticals USA, Inc.	$12,403.23	37	2025
Source payment records 2025-02-06 · Teva Pharmaceuticals USA, Inc. · $2.30 · Open Payments source 2025-02-06 · Teva Pharmaceuticals USA, Inc. · $23.14 · Open Payments source 2025-03-06 · Teva Pharmaceuticals USA, Inc. · $3.25 · Open Payments source 2025-03-06 · Teva Pharmaceuticals USA, Inc. · $22.24 · Open Payments source 2025-03-30 · Teva Pharmaceuticals USA, Inc. · $6,510.00 · Open Payments source 2025-04-03 · Teva Pharmaceuticals USA, Inc. · $2,380.00 · Open Payments source 2025-04-03 · Teva Pharmaceuticals USA, Inc. · $118.75 · Open Payments source 2025-04-03 · Teva Pharmaceuticals USA, Inc. · $22.17 · Open Payments source 2025-04-22 · Teva Pharmaceuticals USA, Inc. · $14.41 · Open Payments source 2025-05-08 · Teva Pharmaceuticals USA, Inc. · $2.43 · Open Payments source 2025-05-08 · Teva Pharmaceuticals USA, Inc. · $23.35 · Open Payments source 2025-05-14 · Teva Pharmaceuticals USA, Inc. · $10.64 · Open Payments source 2025-05-14 · Teva Pharmaceuticals USA, Inc. · $12.20 · Open Payments source 2025-06-05 · Teva Pharmaceuticals USA, Inc. · $26.15 · Open Payments source 2025-06-11 · Teva Pharmaceuticals USA, Inc. · $20.76 · Open Payments source 2025-06-12 · Teva Pharmaceuticals USA, Inc. · $9.13 · Open Payments source 2025-06-25 · Teva Pharmaceuticals USA, Inc. · $22.56 · Open Payments source 2025-07-02 · Teva Pharmaceuticals USA, Inc. · $14.10 · Open Payments source 2025-07-24 · Teva Pharmaceuticals USA, Inc. · $0.63 · Open Payments source 2025-07-24 · Teva Pharmaceuticals USA, Inc. · $24.33 · Open Payments source 2025-08-21 · Teva Pharmaceuticals USA, Inc. · $8.64 · Open Payments source 2025-08-25 · Teva Pharmaceuticals USA, Inc. · $460.00 · Open Payments source 2025-08-27 · Teva Pharmaceuticals USA, Inc. · $23.34 · Open Payments source 2025-09-09 · Teva Pharmaceuticals USA, Inc. · $24.64 · Open Payments source 2025-09-24 · Teva Pharmaceuticals USA, Inc. · $2.51 · Open Payments source 2025-09-24 · Teva Pharmaceuticals USA, Inc. · $3.30 · Open Payments source 2025-09-24 · Teva Pharmaceuticals USA, Inc. · $20.47 · Open Payments source 2025-10-09 · Teva Pharmaceuticals USA, Inc. · $9.66 · Open Payments source 2025-10-14 · Teva Pharmaceuticals USA, Inc. · $2,380.00 · Open Payments source 2025-10-14 · Teva Pharmaceuticals USA, Inc. · $117.89 · Open Payments source 2025-10-16 · Teva Pharmaceuticals USA, Inc. · $35.71 · Open Payments source 2025-10-29 · Teva Pharmaceuticals USA, Inc. · $2.76 · Open Payments source 2025-10-29 · Teva Pharmaceuticals USA, Inc. · $3.78 · Open Payments source 2025-10-29 · Teva Pharmaceuticals USA, Inc. · $21.95 · Open Payments source 2025-11-06 · Teva Pharmaceuticals USA, Inc. · $6.46 · Open Payments source 2025-11-07 · Teva Pharmaceuticals USA, Inc. · $7.50 · Open Payments source 2025-11-11 · Teva Pharmaceuticals USA, Inc. · $12.08 · Open Payments source
LYBALVI Normalized: lybalvi	Drug	Alkermes, Inc.	$468.82	26	2025
Source payment records 2025-01-14 · Alkermes, Inc. · $10.28 · Open Payments source 2025-01-15 · Alkermes, Inc. · $121.85 · Open Payments source 2025-01-22 · Alkermes, Inc. · $9.50 · Open Payments source 2025-01-23 · Alkermes, Inc. · $27.12 · Open Payments source 2025-01-23 · Alkermes, Inc. · $3.94 · Open Payments source 2025-02-13 · Alkermes, Inc. · $20.57 · Open Payments source 2025-03-05 · Alkermes, Inc. · $10.64 · Open Payments source 2025-04-04 · Alkermes, Inc. · $7.94 · Open Payments source 2025-04-10 · Alkermes, Inc. · $16.70 · Open Payments source 2025-04-10 · Alkermes, Inc. · $2.22 · Open Payments source 2025-05-06 · Alkermes, Inc. · $8.13 · Open Payments source 2025-05-15 · Alkermes, Inc. · $26.78 · Open Payments source 2025-06-12 · Alkermes, Inc. · $20.06 · Open Payments source 2025-06-17 · Alkermes, Inc. · $10.74 · Open Payments source 2025-07-09 · Alkermes, Inc. · $22.38 · Open Payments source 2025-07-09 · Alkermes, Inc. · $2.95 · Open Payments source 2025-08-05 · Alkermes, Inc. · $9.65 · Open Payments source 2025-08-20 · Alkermes, Inc. · $14.30 · Open Payments source 2025-09-03 · Alkermes, Inc. · $20.44 · Open Payments source 2025-09-24 · Alkermes, Inc. · $7.18 · Open Payments source 2025-09-24 · Alkermes, Inc. · $5.02 · Open Payments source 2025-10-03 · Alkermes, Inc. · $17.37 · Open Payments source 2025-10-16 · Alkermes, Inc. · $18.94 · Open Payments source 2025-11-19 · Alkermes, Inc. · $16.15 · Open Payments source 2025-12-10 · Alkermes, Inc. · $12.55 · Open Payments source 2025-12-17 · Alkermes, Inc. · $25.42 · Open Payments source
ARISTADA Normalized: aristada	Drug	Alkermes, Inc.	$375.11	26	2025
Source payment records 2025-01-14 · Alkermes, Inc. · $10.28 · Open Payments source 2025-01-22 · Alkermes, Inc. · $9.50 · Open Payments source 2025-01-23 · Alkermes, Inc. · $27.12 · Open Payments source 2025-01-23 · Alkermes, Inc. · $3.94 · Open Payments source 2025-02-13 · Alkermes, Inc. · $20.57 · Open Payments source 2025-03-05 · Alkermes, Inc. · $10.64 · Open Payments source 2025-04-04 · Alkermes, Inc. · $7.94 · Open Payments source 2025-04-10 · Alkermes, Inc. · $16.70 · Open Payments source 2025-04-10 · Alkermes, Inc. · $2.22 · Open Payments source 2025-05-06 · Alkermes, Inc. · $8.13 · Open Payments source 2025-05-15 · Alkermes, Inc. · $26.78 · Open Payments source 2025-06-12 · Alkermes, Inc. · $20.06 · Open Payments source 2025-06-17 · Alkermes, Inc. · $10.74 · Open Payments source 2025-07-09 · Alkermes, Inc. · $22.38 · Open Payments source 2025-07-09 · Alkermes, Inc. · $2.95 · Open Payments source 2025-08-05 · Alkermes, Inc. · $9.65 · Open Payments source 2025-08-20 · Alkermes, Inc. · $14.30 · Open Payments source 2025-09-03 · Alkermes, Inc. · $20.44 · Open Payments source 2025-09-17 · Alkermes, Inc. · $28.14 · Open Payments source 2025-09-24 · Alkermes, Inc. · $7.18 · Open Payments source 2025-09-24 · Alkermes, Inc. · $5.02 · Open Payments source 2025-10-03 · Alkermes, Inc. · $17.37 · Open Payments source 2025-10-16 · Alkermes, Inc. · $18.94 · Open Payments source 2025-11-19 · Alkermes, Inc. · $16.15 · Open Payments source 2025-12-10 · Alkermes, Inc. · $12.55 · Open Payments source 2025-12-17 · Alkermes, Inc. · $25.42 · Open Payments source
REXULTI Normalized: rexulti	Drug	Lundbeck LLC, Otsuka America Pharmaceutical, Inc.	$372.84	21	2025
Source payment records 2025-01-09 · Lundbeck LLC · $24.28 · Open Payments source 2025-01-09 · Lundbeck LLC · $2.44 · Open Payments source 2025-02-20 · Lundbeck LLC · $19.87 · Open Payments source 2025-03-07 · Otsuka America Pharmaceutical, Inc. · $11.31 · Open Payments source 2025-04-08 · Otsuka America Pharmaceutical, Inc. · $20.37 · Open Payments source 2025-04-08 · Lundbeck LLC · $11.63 · Open Payments source 2025-05-06 · Lundbeck LLC · $24.22 · Open Payments source 2025-05-06 · Lundbeck LLC · $0.70 · Open Payments source 2025-05-08 · Otsuka America Pharmaceutical, Inc. · $9.77 · Open Payments source 2025-06-03 · Lundbeck LLC · $22.35 · Open Payments source 2025-06-18 · Lundbeck LLC · $27.39 · Open Payments source 2025-07-08 · Lundbeck LLC · $19.71 · Open Payments source 2025-07-10 · Lundbeck LLC · $20.59 · Open Payments source 2025-07-10 · Lundbeck LLC · $4.11 · Open Payments source 2025-07-15 · Otsuka America Pharmaceutical, Inc. · $18.34 · Open Payments source 2025-08-12 · Lundbeck LLC · $8.65 · Open Payments source 2025-08-20 · Lundbeck LLC · $17.60 · Open Payments source 2025-09-16 · Lundbeck LLC · $30.36 · Open Payments source 2025-10-22 · Lundbeck LLC · $32.84 · Open Payments source 2025-11-20 · Lundbeck LLC · $27.70 · Open Payments source 2025-12-10 · Otsuka America Pharmaceutical, Inc. · $18.61 · Open Payments source
FANAPT Normalized: fanapt	Drug	Vanda Pharmaceuticals Inc.	$340.12	17	2025
Source payment records 2025-02-05 · Vanda Pharmaceuticals Inc. · $29.99 · Open Payments source 2025-04-22 · Vanda Pharmaceuticals Inc. · $5.33 · Open Payments source 2025-04-23 · Vanda Pharmaceuticals Inc. · $27.55 · Open Payments source 2025-07-17 · Vanda Pharmaceuticals Inc. · $25.04 · Open Payments source 2025-07-29 · Vanda Pharmaceuticals Inc. · $18.65 · Open Payments source 2025-08-19 · Vanda Pharmaceuticals Inc. · $24.70 · Open Payments source 2025-09-02 · Vanda Pharmaceuticals Inc. · $17.78 · Open Payments source 2025-09-18 · Vanda Pharmaceuticals Inc. · $12.15 · Open Payments source 2025-09-18 · Vanda Pharmaceuticals Inc. · $13.09 · Open Payments source 2025-10-02 · Vanda Pharmaceuticals Inc. · $21.63 · Open Payments source 2025-10-23 · Vanda Pharmaceuticals Inc. · $1.59 · Open Payments source 2025-10-23 · Vanda Pharmaceuticals Inc. · $29.10 · Open Payments source 2025-10-28 · Vanda Pharmaceuticals Inc. · $17.55 · Open Payments source 2025-11-12 · Vanda Pharmaceuticals Inc. · $16.97 · Open Payments source 2025-11-20 · Vanda Pharmaceuticals Inc. · $30.28 · Open Payments source 2025-12-11 · Vanda Pharmaceuticals Inc. · $30.83 · Open Payments source 2025-12-23 · Vanda Pharmaceuticals Inc. · $17.89 · Open Payments source
COBENFY Normalized: cobenfy	Drug	E.R. Squibb & Sons, L.L.C.	$297.89	13	2025
Source payment records 2025-01-16 · E.R. Squibb & Sons, L.L.C. · $26.78 · Open Payments source 2025-02-20 · E.R. Squibb & Sons, L.L.C. · $13.42 · Open Payments source 2025-04-02 · E.R. Squibb & Sons, L.L.C. · $21.03 · Open Payments source 2025-04-17 · E.R. Squibb & Sons, L.L.C. · $31.79 · Open Payments source 2025-06-11 · E.R. Squibb & Sons, L.L.C. · $14.50 · Open Payments source 2025-07-18 · E.R. Squibb & Sons, L.L.C. · $29.01 · Open Payments source 2025-08-12 · E.R. Squibb & Sons, L.L.C. · $24.07 · Open Payments source 2025-09-10 · E.R. Squibb & Sons, L.L.C. · $16.78 · Open Payments source 2025-09-30 · E.R. Squibb & Sons, L.L.C. · $29.73 · Open Payments source 2025-10-14 · E.R. Squibb & Sons, L.L.C. · $24.88 · Open Payments source 2025-10-21 · E.R. Squibb & Sons, L.L.C. · $18.85 · Open Payments source 2025-11-06 · E.R. Squibb & Sons, L.L.C. · $20.75 · Open Payments source 2025-11-12 · E.R. Squibb & Sons, L.L.C. · $26.30 · Open Payments source
INVEGA SUSTENNA Normalized: invega sustenna	Drug	Janssen Pharmaceuticals, Inc	$215.07	12	2025
Source payment records 2025-02-25 · Janssen Pharmaceuticals, Inc · $25.71 · Open Payments source 2025-02-25 · Janssen Pharmaceuticals, Inc · $2.68 · Open Payments source 2025-04-01 · Janssen Pharmaceuticals, Inc · $30.38 · Open Payments source 2025-06-06 · Janssen Pharmaceuticals, Inc · $14.29 · Open Payments source 2025-06-11 · Janssen Pharmaceuticals, Inc · $14.66 · Open Payments source 2025-07-02 · Janssen Pharmaceuticals, Inc · $1.43 · Open Payments source 2025-07-02 · Janssen Pharmaceuticals, Inc · $1.85 · Open Payments source 2025-07-02 · Janssen Pharmaceuticals, Inc · $19.73 · Open Payments source 2025-08-19 · Janssen Pharmaceuticals, Inc · $16.66 · Open Payments source 2025-09-19 · Janssen Pharmaceuticals, Inc · $26.94 · Open Payments source 2025-10-07 · Janssen Pharmaceuticals, Inc · $26.77 · Open Payments source 2025-11-19 · Janssen Pharmaceuticals, Inc · $33.97 · Open Payments source
REJOYN Normalized: rejoyn	Device	Otsuka Pharmaceutical Development & Commercialization, Inc.	$72.02	3	2025
Source payment records 2025-05-14 · Otsuka Pharmaceutical Development & Commercialization, Inc. · $16.03 · Open Payments source 2025-05-18 · Otsuka Pharmaceutical Development & Commercialization, Inc. · $31.01 · Open Payments source 2025-06-16 · Otsuka Pharmaceutical Development & Commercialization, Inc. · $24.98 · Open Payments source
Auvelity Normalized: auvelity	Drug	Axsome Therapeutics, Inc.	$50.92	2	2025
Source payment records 2025-05-13 · Axsome Therapeutics, Inc. · $26.55 · Open Payments source 2025-06-17 · Axsome Therapeutics, Inc. · $24.37 · Open Payments source
ARISTADA INITIO Normalized: aristada initio	Drug	Alkermes, Inc.	$28.14	1	2025
Source payment records 2025-09-17 · Alkermes, Inc. · $28.14 · Open Payments source
ERZOFRI EXTENDED-RELEASE Normalized: erzofri extended release	Drug	Luye Pharma (USA) Ltd.	$22.84	1	2025
Source payment records 2025-10-09 · Luye Pharma (USA) Ltd. · $22.84 · Open Payments source
TRINTELLIX Normalized: trintellix	Drug	Takeda Pharmaceuticals U.S.A., Inc.	$16.29	1	2025
Source payment records 2025-09-09 · Takeda Pharmaceuticals U.S.A., Inc. · $16.29 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
ABILIFY MAINTENA abilify maintena	2025	Abilify Maintena	2024	86 Beneficiary count suppressed	exact normalized	Medicare Part D
ARISTADA aristada	2025	Aristada	2024	72 Beneficiary count suppressed	exact normalized	Medicare Part D
AUSTEDO XR austedo xr	2025	Austedo Xr	2024	48 Beneficiary count suppressed	exact normalized	Medicare Part D
INGREZZA ingrezza	2025	Ingrezza	2024	16 Beneficiary count suppressed	exact normalized	Medicare Part D
INVEGA SUSTENNA invega sustenna	2025	Invega Sustenna	2024	110 Beneficiary count suppressed	exact normalized	Medicare Part D
LYBALVI lybalvi	2025	Lybalvi	2024	24 Beneficiary count suppressed	exact normalized	Medicare Part D
REXULTI rexulti	2025	Rexulti	2024	44 Beneficiary count suppressed	exact normalized	Medicare Part D
TRINTELLIX trintellix	2025	Trintellix	2024	78	exact normalized	Medicare Part D
UZEDY uzedy	2025	Uzedy	2024	12 Beneficiary count suppressed	exact normalized	Medicare Part D
VRAYLAR vraylar	2025	Vraylar	2024	52 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	VRAYLAR open payments reported associated product	CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550	Vraylar · 2024 Exact normalized brand match · 1 Part D row	52	suppressed by CMS
Alkermes, Inc. Exact reporting entity; no affiliate inference	2025	ARISTADA open payments reported associated product	CMS Open Payments — General Payments 76041 supporting records · 17486 recipient NPIs · example record 1222428566	Aristada · 2024 Exact normalized brand match · 1 Part D row	72	suppressed by CMS
Alkermes, Inc. Exact reporting entity; no affiliate inference	2025	LYBALVI open payments reported associated product	CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566	Lybalvi · 2024 Exact normalized brand match · 1 Part D row	24	suppressed by CMS
Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference	2025	INVEGA SUSTENNA open payments reported associated product	CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262	Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row	110	suppressed by CMS
Lundbeck LLC Exact reporting entity; no affiliate inference	2025	ABILIFY MAINTENA open payments reported associated product	CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994	Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row	86	suppressed by CMS
Lundbeck LLC Exact reporting entity; no affiliate inference	2025	REXULTI open payments reported associated product	CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986	Rexulti · 2024 Exact normalized brand match · 1 Part D row	44	suppressed by CMS
Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference	2025	INGREZZA open payments reported associated product	CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729	Ingrezza · 2024 Exact normalized brand match · 1 Part D row	16	suppressed by CMS
Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference	2025	ABILIFY MAINTENA open payments reported associated product	CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721	Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row	86	suppressed by CMS
Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference	2025	REXULTI open payments reported associated product	CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708	Rexulti · 2024 Exact normalized brand match · 1 Part D row	44	suppressed by CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference	2025	ABILIFY MAINTENA open payments reported associated product	CMS Open Payments — General Payments 87 supporting records · 83 recipient NPIs · example record 1225319985	Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row	86	suppressed by CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference	2025	REXULTI open payments reported associated product	CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865	Rexulti · 2024 Exact normalized brand match · 1 Part D row	44	suppressed by CMS
Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference	2025	TRINTELLIX open payments reported associated product	CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266	Trintellix · 2024 Exact normalized brand match · 1 Part D row	78	11
Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference	2025	AUSTEDO XR open payments reported associated product	CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228	Austedo Xr · 2024 Exact normalized brand match · 1 Part D row	48	suppressed by CMS
Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference	2025	UZEDY open payments reported associated product	CMS Open Payments — General Payments 46702 supporting records · 13355 recipient NPIs · example record 1247244226	Uzedy · 2024 Exact normalized brand match · 1 Part D row	12	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Quetiapine Fumarate	Quetiapine Fumarate	549	79
Clonazepam	Clonazepam	232	30
Trazodone Hcl	Trazodone Hcl	154	32
Lorazepam	Lorazepam	114	20
Invega Sustenna	Paliperidone Palmitate	110	suppressed
Bupropion Xl	Bupropion Hcl	109	14
Zolpidem Tartrate	Zolpidem Tartrate	87	13
Abilify Maintena	Aripiprazole	86	suppressed
Mirtazapine	Mirtazapine	84	14
Olanzapine	Olanzapine	82	17
Risperidone	Risperidone	82	17
Gabapentin	Gabapentin	79	suppressed
Trintellix	Vortioxetine Hydrobromide	78	11
Aristada	Aripiprazole Lauroxil	72	suppressed
Aripiprazole	Aripiprazole	71	17
Paroxetine Hcl	Paroxetine Hcl	70	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	69	11
Alprazolam	Alprazolam	68	suppressed
Benztropine Mesylate	Benztropine Mesylate	68	13
Escitalopram Oxalate	Escitalopram Oxalate	67	suppressed
Duloxetine Hcl	Duloxetine Hcl	61	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	59	suppressed
Diazepam	Diazepam	53	suppressed
Vraylar	Cariprazine Hcl	52	suppressed
Divalproex Sodium Er	Divalproex Sodium	51	12
Ibuprofen	Ibuprofen	50	suppressed
Donepezil Hcl	Donepezil Hcl	49	suppressed
Austedo Xr	Deutetrabenazine	48	suppressed
Lurasidone Hcl	Lurasidone Hcl	48	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	47	suppressed
Rexulti	Brexpiprazole	44	suppressed
Ziprasidone Hcl	Ziprasidone Hcl	37	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	35	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	35	suppressed
Sertraline Hcl	Sertraline Hcl	35	suppressed
Buspirone Hcl	Buspirone Hcl	34	suppressed
Citalopram Hbr	Citalopram Hydrobromide	33	suppressed
Clozapine	Clozapine	31	suppressed
Bupropion Hcl Sr	Bupropion Hcl	30	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	28	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	28	11
Amitriptyline Hcl	Amitriptyline Hcl	24	suppressed
Lybalvi	Olanzapine/Samidorphan Malate	24	suppressed
Divalproex Sodium	Divalproex Sodium	22	suppressed
Doxepin Hcl	Doxepin Hcl	19	suppressed
Carbamazepine	Carbamazepine	16	suppressed
Ingrezza	Valbenazine Tosylate	16	suppressed
Temazepam	Temazepam	16	suppressed
Memantine Hcl	Memantine Hcl	14	suppressed
Fetzima	Levomilnacipran Hcl	13	suppressed
Lamotrigine	Lamotrigine	13	suppressed
Paliperidone Er	Paliperidone	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Celecoxib	Celecoxib	12	suppressed
Uzedy	Risperidone	12	suppressed
Fluphenazine Hcl	Fluphenazine Hcl	11	suppressed
Haloperidol	Haloperidol	11	suppressed
Lithium Carbonate	Lithium Carbonate	11	suppressed
Naltrexone Hcl	Naltrexone Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$99,484.04 · 298 records	Teva Pharmaceuticals USA, Inc.	ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, ARISTADA INITIO, AUSTEDO XR, Auvelity, CAPLYTA, COBENFY, ERZOFRI EXTENDED-RELEASE, FANAPT, INGREZZA, INVEGA SUSTENNA, LYBALVI, REJOYN, REXULTI, TRINTELLIX, UZEDY, VRAYLAR	14	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Abilify Maintena play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error